SUZHOU and SHANGHAI China, Feb 6, 2023 -Forlong Biotechnology, a biotech dedicated to developing next-generation cytokine therapeutics, today announced that it raised $15 million in a Series A financing. The round was led by Puhua Capital, with participation from additional investors including Co-win Capital etc.

Forlong is an innovative R&D company driven by synthetic immunology，The company is backed by a world-renowned protein-drug-discovery laboratory and its founding team possesses deep scientific translation expertise. With core members who have spent decades in innovative-drug development, Forlong has extensive industrialization experience.

It has built a globally leading, integrated synthetic-immunology technology system that has spawned four core platforms: the F-body long-acting platform, the synthetic novel-cytokine platform, the Fc-engineering platform, and the biomolecular artificial-evolution platform. Together these technologies enable multi-dimensional optimization of cytokine-based protein therapeutics to yield best-in-class products. The lead asset, FL115 (IL-15 super agonist), has demonstrated pre-clinical safety and efficacy that significantly outperform the field’s benchmark molecules.

With the support of this round of funding, Forlong Biotech will also continue to increase its R&D investment, accelerate the IND application and clinical development of its lead product pipeline FL115, and continuously expand its presence in the field of cytokines and other protein drugs.

About Forlong Biotechnology

Forlong Biotechnology is a biotechnology company dedicated to developing next-generation cytokine therapeutics. Based on synthetic immunology, the company has established four core technology platforms, committed to overcoming the challenges of developing cytokine drugs.